Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung
Executive Summary
New data for AMG 510 at ESMO show the drug is more active in lung than colorectal cancer, as was reported at ASCO, but Amgen's Greg Friberg notes that Phase I monotherapy and planned combination studies may shed more light on KRAS biology and efficacy in different tumor types.
You may also be interested in...
Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field
Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients.
Amgen’s Lumakras Falls Short Of Mirati’s Adagrasib In Pancreatic Cancer
The firm’s first-in-class KRAS inhibitor has shown lower objective response rates than Mirati’s rival candidate in a Phase I/II pancreatic cancer study, but experts note that its lung cancer opportunity, where Amgen can build up a considerable lead, is larger.
Lumakras A Big Focus For Amgen; More Data Coming Soon
Amgen reported 5% year-over-year revenue growth to $6.5bn in the second quarter, up 11% from Q1. It did not break out Lumakras sales but detailed upcoming data that may support future indications.